· Dolphin Sutures

PFAS, phthalates and the slow squeeze on device materials

Chemical restriction regimes written for consumer products increasingly reach medical devices. PTFE, plasticisers and the substitution problem nobody has fully solved.

Laboratory glassware with a bottle carrying a toxic-hazard symbol

Most regulatory pressure on medical devices comes from device regulation. A separate and growing source comes from chemicals regulation — restriction regimes written primarily with consumer and industrial products in mind, which increasingly reach materials that devices depend on.

Why PFAS is the difficult one

Per- and polyfluoroalkyl substances are a large family of fluorinated chemicals valued for chemical inertness, thermal stability, low friction and water repellency. They are also environmentally persistent, and restriction proposals in Europe and elsewhere have been drafted broadly enough to capture the family as a class rather than substance by substance.

The difficulty for devices is that PFAS chemistry sits in places where its properties are the reason the device works. Expanded PTFE is used in vascular grafts and as a barrier layer in composite hernia mesh. Fluoropolymer coatings reduce friction on guidewires and needles. Fluorinated materials appear in filtration membranes, in seals and gaskets on processing equipment, and in the release coatings used in manufacturing rather than in the finished device.

A class-wide restriction therefore touches finished devices, manufacturing aids and the equipment used to make unrelated products, which is why the medical device sector has argued for derogations and why those arguments turn on the absence of substitutes rather than on cost.

Phthalates, and how that one went

The phthalate story is instructive because it is further along. DEHP, used as a plasticiser to make PVC flexible, is a reproductive toxicant under European classification and has been progressively restricted. PVC tubing, bags and catheters were built around it.

The response has been substitution — alternative plasticisers, and alternative base polymers where the plasticiser cannot be replaced. That transition has taken more than a decade, is not complete, and required a great deal of requalification work on materials that were, functionally, working. It is a reasonable model for how the PFAS transition will proceed: slower than the regulation, faster than the industry expects, and expensive in engineering time rather than in materials.

What substitution actually costs

This is the part that is consistently underestimated outside manufacturing, and it is worth spelling out. Changing a material in a medical device is not procurement.

  • Biological safety evaluation has to be revisited, because a new material has a different chemical characterisation, different extractables and leachables, and potentially a different biological profile.
  • Performance verification has to be repeated, because a substitute chosen to match one property rarely matches all of them.
  • Sterilisation compatibility has to be reconfirmed — a new polymer may respond differently to radiation or to gas.
  • Shelf life and ageing data may need regenerating, because degradation behaviour is material-specific.
  • Regulatory notification or approval is required where the material is described in the technical documentation.
  • Supply chain qualification has to be done for the new material, at volume, with the reliability the old one had.

For a device family with many variants, that programme runs into years. And it is being asked for across many materials at once, which is why the sector’s response has been to seek time rather than exemption.

The transparency requirement underneath

A quieter change is that manufacturers are increasingly required to know, and to be able to state, what is actually in their products. Substance declarations, chemical characterisation as part of biological evaluation, and specific labelling requirements for certain substances of concern all point the same way.

That is harder than it sounds for anyone with a deep supply chain. The obligation ultimately requires a manufacturer to know the composition of materials several tiers back, and suppliers have historically treated formulations as proprietary. A significant part of the practical work in this area is contractual rather than technical.

What to watch

The scope and timing of the European PFAS restriction, and whether medical derogations survive in the final text, is the largest single variable. Beyond it, the pattern is a steady widening of substance-level restrictions and a steady increase in required disclosure.

The strategic implication for a manufacturer is unglamorous and clear: material knowledge is becoming a regulatory asset. Knowing precisely what is in a device, where each material comes from and what would replace it is no longer purely an engineering matter. It is the thing that determines how quickly a company can respond when a material it depends on is restricted.


This article summarises developments reported publicly across the medical-device trade press, conference programmes and clinical literature. It is general professional information — not clinical guidance, and not a claim about any Dolphin Sutures product. Device selection, indications and technique rest with the treating surgeon; refer to the Instructions for Use supplied with any device.

Talk to our team

Bulk pricing, OEM manufacturing and export documentation — response within one business day.